




References

***As you climb the ladder of success be sure its leaning
against the right building.***

1. Montgomery JA, Johnston TP and Fulmer Y. In Burgers Medicinal chemistry Wolff ME (ed.), Part II, 4th ed., John Wiley and Sons, New York, 1979, 596-670.
2. Lenhard, RE, Osteen, RT and Gansler, T. (Eds.): The American Cancer Society's Clinical Oncology (2001). The American Cancer Society, Atlanta, Georgia.
3. Robbins SL and Kumar V. Basic Pathology, 4th ed. Philadelphia. WB Saunders, 1987, 194-268.
4. Small EJ and Vogelzang NJ. Second-Line hormonal therapy for advanced prostate cancer: a shifting paradigm. **J Clin Oncol**, 1997, 15, 382-388.
5. Greenlee RT. Cancer statistics. **CA Cancer J Clin**, 2000, 50, 7.
6. Parker SL, Tong T and Bolden S. Cancer Statistic. **CA Cancer J Clin**, 1996, 65, 5-27.
7. Jemel A, Samuals A, Ghafoor A, Ward E and Thun M. Cancer statistics. **CA Cancer J Clin**, 2003, 53, 5-26.
8. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current Status and Future Prospects. **The Prostate**, 2004, 9999, 1-22.
9. Lynn S and Baker WB. You and leukemia, a day at a time. Saunders Co., 1988, ISBN 0-7216-1495-7.
10. The American Cancer Society. Facts and Figures 2002.
11. Bangham AD, Standish HM and Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. **J. Mol. Biol.** 1965, 13, 238-252.

12. Gregoriadis G, Wills EJ, Swain CP and Tavill AS. Drug carrier potential of liposomes in cancer chemotherapy. **Lancet**, 1974, I, 1313–1316.
13. Bangham AD and Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. **J. Mol. Biol.** 1964, 8, 660–668.
14. Gregoriadis G and Florence AT. Liposomes in drug delivery: Clinical, diagnostic and ophthalmic potential. **Drugs**. 1993, 45, 15–28.
15. Lasic DD and Papahadjopoulos D. Liposomes revisited. **Science** 1995, 267, 1275–1276.
16. Sharma A and Sharma US. Liposomes in drug delivery: progress and limitations. **Int J Pharm.** 1997, 154, 123–140.
17. Ohsawa T, Miura H and Harada K. A novel method for preparing liposome with a high capacity to encapsulate proteinous drugs: freeze-drying method. **Chem. Pharm. Bull.** 1984, 32, 2442–2445.
18. Papahadjopoulos D and Watkins JC. Phospholipid model membranes. II. Permeability properties of hydrated liquid crystals. **Biochim. Biophys. Acta** 1967, 135, 639–652.
19. Gruner SM, Lenk RP, Janoff AS and Ostro MJ. Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles. **Biochemistry** 1985, 24, 2833–2842.
20. Clerc S and Barenholz Y. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. **Biochim. Biophys. Acta** 1995, 1240, 257–265.
21. Mayer LD, Tai LC, Bally MB, Mitlenes GN, Ginsberg RS and Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. **Biochim. Biophys. Acta** 1990, 1025, 143–151.

-
22. Mayhew EG, Lasic D, Babbar S and Martin FJ. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. **Int. J. Cancer** 1992, 51, 302–309.
 23. Szoka F. Jr and Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). **Ann. Rev. Biophys. Bioeng.** 1980, 9, 467–508.
 24. Deamer D and Uster P. Liposome preparation methods and monitoring liposome fusion. In: Baserga, R., Croce, C. and Royeza, G. (Eds.), *Introduction of Macromolecules into viable Mammalian Cells*, Alan R. Liss, New York, 1980, pp. 205–220.
 25. Martin FJ. Pharmaceutical manufacturing of liposomes. In: Tyle, P. (Ed.), *Specialized Drug Delivery System: Manufacturing and Production Technology*, Marcell Dekker, New York, 1990, pp. 267–316.
 26. New RRC. Preparation of liposomes. In: New, R.R.C. (Ed.), *Liposomes: a practical approach*, IRL Press, Oxford, 1990, pp. 33–104.
 27. Gregoriadis G and Ryman BE. Fate of protein containing liposomes injected into rats. **Eur J Biochemistry.** 1971, 24, 485–91.
 28. Blume G and Cave G. Liposomes for sustained drug release *in vivo*. **Biochim Biophys Acta** 1990, 1029, 91–97.
 29. Hershfield MS and Buckley K. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. **N Engl J Med** 1987, 316, 589–96.
 30. Klibanov AL, Maruyama K, Torchilin VP and Huang L. Amphipathic polyethylene glycols effectively prolong circulation time of liposomes. **FEBS Lett** 1990, 268, 235–7.

31. Mayhew E, Lasic D, Babbav S and Martin FJ. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long circulating liposomes incorporating a polyethylene glycol derivatized phospholipid. **Int J Cancer** 1992, 51, 302-9.
32. Papahadjopoulos D, Allen TM and Gabizon A. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. **Proc Natl Acad Sci (USA)** 1991, 88, 11460-4.
33. Senior J, Delcada C, Fischer D, Tilcock C and Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly (EG)-coated vesicles. **Biochim Biophys Acta** 1991, 1062, 79-82.
34. Mori A, Klivanov AL, Torchilin VP and Hung L. Influence of steric barrier activity of amphipathic poly (ethylene glycol) and ganglioside GMI on the circulation time of liposomes and on the target binding of immunoliposomes *in vivo*. **FEBS Lett** 1991, 284, 263-6.
35. Allen TM, Hansen C, Martin F, Redeman C and Yau-Young A. Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives *in vivo*. **Biochim Biophys Acta** 1991, 1066, 29-36.
36. Allen TM, Austen GA, Chonn A, Liu L and Lea KC. Uptake of liposomes by cultured mouse bone marrow macrophages: Influence of liposome composition and size. **Biochim Biophys Acta** 1991, 1061, 56-64.
37. Vaage J, Mayhow E, Lasic D and Martin F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. **Int J Cancer** 1992, 51, 2431-9.

38. Lee JH, Kopecek J and Andrade JD. Solution technique to incorporate polyethylene oxide and other water-soluble polymers into surface of polymeric biomaterials. **Biomaterials** 1991,12,144-53.
39. Prime KL and Whiteside GM. Self-assembled organic monolayers: Model systems for studying adsorption of proteins at surfaces. **Science** 1991, 252, 1164-7.
40. Desai NP and Bubble JA. Biological responses to polyethylene oxide modified polyethylene tetra phthalate surfaces. **Biomed Mater Res** 1991, 25, 829-43.
41. Gregoriadis G. Targeting of drugs. **Nature** 1977, 265, 407-10.
42. Rahman Y and Wright BJ. Liposomes containing chelating agents. **J Cell Biology** 1975, 65, 112-22.
43. Brenda E, Ryman RF and Jeyasingh JK. Potential applications of liposomes to therapy. **Ann N Y Acad Sci** 1978, 308, 281-307.
44. Needham D, McIntosh JJ and Lasic D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. **Biochim Biophys Acta** 1992, 1108, 40-8.
45. Allen TM, Hansen C and Rutledge J. Liposomes with prolonged circulation time: factors affecting uptake by reticuloendothelial and other tissues. **Biochim Biophys Acta** 1989, 981, 27-35.
46. Gabizon A and Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. **Proc Natl Acad Sci (USA)** 1988, 85, 6949-53.
47. Park YS, Maruyama K and Huang L. Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. **Biochim Biophys Acta** 1992, 1108, 257-60.

-
48. Allen TM, Hansen C, Martin F, Redeman C and Yau-Young A. Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo. **Biochim Biophys Acta** 1991, 1066, 29-36.
 49. Woodle MC and Lasic DD. Sterically Stabilized Liposomes. **Biochim. Biophys. Acta** 1992, 1113, 171-199.
 50. Blume G and Cevc G. Molecular mechanism of the lipid vesicles longevity in vivo. **Biochim. Biophys. Acta** 1993, 1146, 157-168.
 51. Desai NP and Hubbell JA. Solution technique to incorporate polyethylene oxide and other water-soluble polymers in to surfaces of polymeric biomaterials. **Biomaterials** 1991, 12, 144-153.
 52. Mori A, Klivanov AL, Torchilin VP and Huang L. Influence of the steric barrier activity of amphipathic poly (ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. **FEBS Lett.** 1991, 284, 263-266.
 53. Klivanov AL, Maruyama K, Beckerleg AM, Torchilin VP and Huang L. Activity of amphiphilic polyethylene glycol 5000 to prolong the circulation time of liposomes depends on the liposomes size and is unfavorable for immunoliposomes binding to target. **Biochim. Biophys. Acta** 1991, 1062, 142-148.
 54. Maruyama K, Yuda T, Okamoto A, Ishikura C, Kojima S and Iwatsuru M. Effect of molecular weight in amphipathic polyethylene glycol on prolonging the circulation time of large unilamellar liposomes. **Chem. Pharm. Bull.** 1991, 396, 1620-1622.
 55. T.M. Allen, C. Hansen, F. Martin, C. Redemann, A and Y. Young. Liposomes containing synthetic lipid derivative of poly (ethylene) show

- prolonged circulation half-lives in vivo. **Biochim. Biophys. Acta** 1991, 1066, 29–36.
56. Schreier H, Abra RM, Kaplan JE and Hunt CA. Liposomes: From biophysics to therapeutics. **Int. J. Pharm.** 1987, 37, 233–238.
57. Illum L, Jacobsen LO, Muller RH, Mak E and Davis SS. Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. **Biomaterials** 1987, 8, 113–117.
58. Jeon SI, Lee JH, Andrade JD and de Gennes PG. **J. Colloid Interface Sci.** 1991, 142, 149–158.
59. Hong Du, Chandaroy P and Wen Hui S. Grafted poly- ethylene glycol on lipid surfaces inhibits protein adsorption and cell adhesion. **Biochim et Biophys Acta** 1997, 1326, 236–248.
60. Srinath P and Diwan PV. Stealth liposomes-an overview. **Ind J Pharmacol.** 1994, 26, 179 – 184.
61. Allen TM. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. **Biochim Biophys Acta** 1981, 640, 385-97.
62. Allen TM, William P and Schlegel RA. Phosphatidyl serine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte membrane. **Proc Natl Acad Sci (USA)** 1988, 85, 8067-71.
63. Sharma A, Mayhew E and Straubinger RM. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. **Cancer Res.** 1993, 53, 5877–5881.
64. Sharma A. Liposomal delivery of antineoplastic drugs: preparation, characterization and antitumor activity of liposomal drug formulations. Ph.D. Thesis, State University of New York at Buffalo, 1994.

-
65. Sharma A, Straubinger RM, Ojima I and Bernacki RJ. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. **J. Pharm. Sci.** 1995, 84, 1400–1404.
 66. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A and Bernacki RJ. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. **Int. J. Cancer.** 1997, 71, 103–107.
 67. Heath TD and Brown CS. Liposome dependent delivery of N-(phosphonacetyl)-L-aspartic acid to cells in vitro. **J. Liposome Res.** 1989, 1, 303–317.
 68. White JC and Hines LH. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis. **Cancer Res.** 1984, 44, 507–513.
 69. Sharma A, Straubinger NL and Straubinger RM. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl) L aspartate (PALA) by liposome drug carriers. **Pharm. Res.** 1993, 10, 1434–1441.
 70. Allen TM, Mehra T, Hansen C and Chin YC. Stealth liposomes: an improved sustained release system for 1- beta-D arabino furanosyl cytosine. **Cancer Res.** 1992, 52, 2431–2439.
 71. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. **Science** 1995, 270, 404–410.
 72. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM and Danielsen M. Lipofection: a highly efficient, lipidmediated DNA-transfection procedure. **Proc. Natl. Acad. Sci. USA** 1987, 84, 7413–7417.
 73. Felgner PL and Ringold GM. Cationic liposome-mediated transfection. **Nature** 1989, 377, 387–388.

74. Felgner PL, Zangg RH and Norman JA. Synthetic recombinant DNA delivery for cancer therapeutics. **Cancer Gene Ther.** 1995, 2, 61–65.
75. Gao X and Huang L. Cationic liposome-mediated gene transfer. **Gene Ther.** 1995, 2, 710–722.
76. Nabel GJ, Chang AE, Hersh EM, Vogeizang NJ, Rubin J, Silver H, Stah S and Schreiber AB. Combined experience from Phase I studies with Allovectin- 7, a direct gene transfer immunotherapeutic, in patients with metastatic solid tumors. **Proc. Annu. Meet. Am. Soc. Clin. Oncol.** 1995, 14, A582.
77. Szoka FC. Liposomal drug delivery: current status and future prospects. In: Wilschut, J, Hoekstra D. (Eds.), *Membrane Fusion*, Marcel Dekker, New York, 1991, pp. 845–890.
78. Ehrlich P. The relations existing between chemical constitution, distribution and pharmacological action. In Ehrlich, P. (Ed.), *Collected Studies on Immunity*, Vol. 2, Wiley, New York, 1906, pp. 404–443.
79. Alving CR. Liposomes as carriers of antigens and adjuvants. **J. Immunol. Methods** 1991, 140, 1–13.
80. Killion JJ and Fidler IJ. Systemic targeting of liposome encapsulated immunomodulators to macrophages for treatment of cancer metastasis. **Immunomethods**, 1994, 4, 273– 279.
81. Binder J, Mishina EV, Jusko WJ and Kupiec-Weglinski JW. Prolongation of cardiac allograft survival in rats by liposome encapsulated methylprednisolone. **Transplantation** 1994, 58, 633–635.
82. Vingerhoeds MH, Steerenberg PA, Hendriks JJGS, Crommelin DJA and Storm G. Targeted delivery of diphtheria toxin via immunoliposomes:

- efficient antitumor activity in the presence of inactivating anti-diphtheria toxin antibodies. **FEBS Letter** 1996, 395, 245–250.
83. Lasic DD and Papahadjopoulos D. Liposomes revisited. **Science** 1995, 267, 1275–1276.
84. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. **Trends Biotechnol** 1995, 13, 527–537.
85. Ahmad I, Longenecker M, Samuel J and Allen TM. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. **Cancer Res.** 1993, 53, 1484–1488.
86. Torchilin VP, Narula J, Halpern E and Khaw BA. Poly (ethylene glycol)-coated anti-cardiac myosin immunoliposomes—factors influencing targeted accumulation in the infarcted myocardium. **Biochim. Biophys. Acta** 1996, 1279, 75–83.
87. Dedrick RL, Myers CE, Bungay PM and DeVita VT. Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. **Cancer Treat. Rep.** 1978, 62, 1–11.
88. Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L and Lewis JL. Intraperitoneal therapy in the management of ovarian cancer. **J. Biol. Med.** 1989, 62, 393–403.
89. Forssen EA and Tokes ZA. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. **Cancer Treat. Rep.** 1983, 67, 481–484.
90. Sharma A, Sharma US and Straubinger RM. Paclitaxel- liposomes for local treatment of intraperitoneal P388 leukemia. **Cancer lett.** 1996, 107, 265–272.
91. Allison AC and Gregoriadis G. Liposomes as immunological adjuvants. **Nature** 1974, 252, 252.

-
92. Alving CR. Liposomes as carriers of antigens and adjuvants. **J. Immunol. Methods** 1991, 140, 1–13.
 93. Kersten GFA and Crommelin DJA. Liposomes and ISCOMS as vaccine formulations. **Biochim. Biophys. Acta** 1995, 1241, 117–138.
 94. Gregoriadis G. and Panagiotidi C. Immunoadjuvant action of liposomes: comparison with other adjuvants. **Immunol. Lett.** 1989, 20, 237–240.
 95. Kraaijeveld CA, Schilham M, Jansen J, Benaissa-Trouw B, Harmsen M, van Houte AJ and Snippe H. The effect of liposomal charge on the neutralizing antibody response against inactivated encephalomyocarditis and semliki forest viruses. **Clin. Exp. Immunol.** 1984, 56, 509–514.
 96. Yasuda T, Dancey GF and Kinsky SC. Immunogenicity of liposomal model membranes in mice: dependence on phospholipid composition. **Proc. Natl. Acad. Sci. USA** 1977, 74, 1234–1236.
 97. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A and Bernacki RJ. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. **Int. J. Cancer.** 1997, 71, 103–107.
 98. Straubinger R, Sharma A, Mayhew E, Taxol Formulation. US Patent 5, 415 869, 16 May, 1995.
 99. Zuidam NJ, Lee SS and Crommelin DJ. Gamma-irradiation of non-frozen, frozen, and freeze-dried liposomes. **Pharm Res.** 1995, 12, 1761–1768.
 100. Zuidam NJ, Lee SS and Crommelin DJ. Sterilization of liposomes by heat treatment. **Pharm. Res.** 1993, 10, 1591–1596.
 101. Mayer LD, Bally MB and Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. **Biochim. Biophys. Acta** 1986, 857, 123–126.

102. Clerc S and Barenholz Y. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. **Biochim. Biophys. Acta** 1995, 1240, 257–265.
103. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI and Barenholz Y. Preparation and characterization of doxorubicin loaded sterically stabilized immunoliposomes. **Pharm. Res.** 1996, 13, 352–359.
104. Giesecke T and Hynynen K. Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro. **Ultrasound in Med. & Biol.** 2003, 29(9), 1359-1365.
105. Raishinghani A and DeMaria AN, **American Journal of Cardiology** 2002, 90, 3J-7J.
106. D'Arrigo JS, Simon RH and Ho SY. Lipid coated microbubbles for earlier sonographic detection of brain tumors. **J Neuroimaging**, 1991,1, 134-139.
107. Feinstein SB, Lang RM and Dick C. Contrast echocardiography during coronary arteriography in humans: Perfusion and anatomic studies. **J Am Coll Cardiol.** 1998, 11, 59-65.
108. Burkand ME and Van Liew HD. Oxygen transport to tissue by persistent bubbles: theory and simulations. **J Appl. Physiol.** 1994, 77, 2874-2878.
109. Klibanov et al. Polyethylene glycol or PEG to prolong the circulation time of liposomes. **FEBS Letters**, 1990, 268(1): 235-237.
110. Gramiak R and Shah PM. Echocardiography of the aortic root. **Invest. Radiol.** 1968, 3(5), 356-366.
111. Gasparine C, Bertolotto M and Croce SL. Evaluation of liver parenchymal blood flow with contrast enhanced ultrasound: preliminary results in healthy and cirrhotic patients. **Acad Radiol.** 2003, 10: 869-876.

112. Biomley MJK, Albrecht T and Cosgrove DO. Liver vascular transit time analyzed with dynamic hepatic venography with bolus injection of ultrasound contrast agent: early experience of 7 patients with metastasis. **Radiology**, 1998, 209, 862-866.
113. Biomley MJK, Albrecht T, Cosgrove DO, et al. Non invasive diagnosis of hepatic cirrhosis by transit time analysis of an ultrasound contrast agent. **Lancet** 1999, 353(9164): 1579-1583.
114. Casley K. The emergence of smart microbubble. **Cardio Res.** 2003, 13-14.
115. Dijkmans PA, Juffermans LJ, Musters RJ, Wamel A and Cate FJ. Microbubbles and ultrasound: from diagnosis to therapy. **Eur. J. Echocardi.** (2004) In Press.
116. Feigenbaum H, Stone J, Nasser W and Chang S. Identification of ultrasound echoes from the left ventricle by use of inter cardiac injections of indocyanine green. **Circulation** 41, 615-621.
117. Unger EC, Matsunaga TO, McCreery T, Schumann P. Therapeutic applications of microbubbles. **Eur J Radiol.** 42, 160-168, 2002.
118. Klivanov AL. Targeted delivery of gas-filled microspheres, contrast agents for ultrasound imaging. **Adv. Drug. Del. Reviews**, 37, 139-157, (1999).
119. Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery. Local drug and gene delivery through microbubbles. **Progress in Cardiovascular Diseases.** 44(1), 45-54, 2001.
120. www.rad.uab.edu
121. William AR, Kubowicz G, Cramer E, Schief R. The effect of microbubble suspension SH U 454 (Echovist) on ultrasound induced cell lysis in a rotating tube exposure system. **Echocardiography**, 8(4), 423-33, 1991.

-
122. Oeffinger BE and Wheatley MA. Development and characterization of nano-scale contrast agent. **Ultrasonic**, 2004, In Press.
 123. Schlieff S and Tanford C. 1973. The Hydrophobic Effect: Formation of Micelles and Biological Membranes. Wiley, New York.
 124. Raisinghani A and DeMaria AN. **Am J Cardiol**, 2002,90, 3J-7J.
 125. Shoros S, Moran CM, Pye SD and McDicken WN. The behavior of individual contrast agent microbubbles. **Ultrasound in Med. & Biol.**, 2003, 29(5), 684-694.
 126. Porter TR, Oberdorfer J, Rafter P, Lof J and Xie F. Microbubble responses to a similar mechanical index with different real time perfusion imaging techniques. **Ultrasound in Med. & Biol.**, 2003, 29(8), 1187-1192.
 127. Dirven HAAM, Rasmussen H, Johnson H and Videm S. Intestinal and hepatic lesions in mice, rats and other laboratory animals after intravenous administration of gas-carrier contrast agents used in ultrasound imaging. **Toxicol and Appl Pharma**. 2003, 188, 165-175,.
 128. Nanda NC, Schlieff R and Goldberg BB. Advances in echo imaging using contrast enhancement. 2nd ed. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1997.
 129. Halpern EJ, Forsberg F, Frauscher F, Merton DA and Liu JB. Gray scale harmonic imaging of prostatic blood flow during infusion of Imagent®. **Ultrasound in Med. & Biol.**, 2003, 29 (5S), S95-S111.
 130. Sontum PC, Ostensen J, Dyrstad K and Hoff L. Acoustic properties of NC100100 and their relation with the microbubble size distribution. **Invest. Radiol**. 1999, 34(4), 268-275.

131. Chen S, Shohet RV and Bekeradjian R. Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid DNA by ultrasound targeted microbubble destruction. **J Am Col Cardiol.** 2001, 42(2), 301-308.
132. Unger EC, McCreery TP, Sweitzer RH, Caldwell VE, Wu Y. Acoustically active lipospheres containing paclitaxel: A new therapeutic ultrasound contrast agent. **Invest. Radiol.** 1998, 33, 886-892.
133. www.edgaronline.com
134. Bjerknes K, Sontum PC, Smistad G, Agerkvist I. Preparation of polymeric micorbubbles: formulation studies and product characterization. **Int. J Pharm.** 1997, 158, 129-136.
135. Cheirif J. Myocardial contrast echocardiography with triggered ultrasound does not cause premature ventricular complexes: evidence from PB 127 studies. **J Am Col Cardiol.** 2002, 39(5), 363A.
136. Feinstein SB. Ultrasonic imaging agent and method of preparation. U.S. Patent No. 4,774,958, 1986.
137. Feinstein et al. Two-dimensional contrast echocardiography. I: in vitro development and quantitative analysis of echo contrast agents. **J Am Col Cardiol**, 1984, 3(1), 14-20.
138. Epstein PS and Plesset MS. On the stability of gas bubbles in liquid-gas solutions. **J.Chem. Phys.** 1950, 18, 1505-1509.
139. Fox et al. **The Journal of Acoustical Society of America**, 1954, 26 (6), 984-989.
140. Strasberg M. **The Journal of Acoustical Society of America**, 1960, 31(2) 163-172.
141. Manley et al. **British Journal of Applied Physics** 1960, 11: 38-42.

142. Cerny D, Mills GJ, Westkaemper PJ. Continuous sonication method for preparation of protein coated microbubbles. U.S. Patent No. 4,957,656, 1990.
143. Wheatley MA, Peng S, Singhal S, Goldberg BB. Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same. U.S. Patent No. 5,352,436, 1994.
144. D'Arrigo JS. Surfactant mixtures, stable gas in liquid emulsions, and methods for the production of such emulsions from said mixtures. U.S. Patent No. 4,684,479, 1987.
145. Soetanto K. Method for the preparation of microbubble-type ultrasonic contrast agent by surfactant. U.S. Patent No. 5,985,247, 1999.
146. Seemann S, Hauff P, Schultze-Mosgau M, Lehmann C, Reszka R. Pharmaceutical Evaluation of Gas-filled microparticles as gene delivery system. **Pharm. Res.** 2002, 19(3), 250-257,.
147. Farnand JR, Puddington IE. Preparation of hollow spherical particles. **Powder Technol.**, 1979, 22, 11-16.
148. Schneider M, Bussat P, Barrau MB, et al. A new ultrasound contrast agent based on biodegradable polymeric microballons. **Inves. Radiol.** 1991, 26, 190-191.
149. Schneider M, Bussat P, Barrau MB, et al. Polymeric microballons as ultrasound contrast agents. Physical and ultrasonic properties compared with sonicated albumin. **Invest. Radiol.** 1992, 27, 134-139.
150. Porter TR, Iversen PL, Li S and Xie F. Interaction of diagnostic ultrasound with synthetic oligonucleotides labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. **J Ultrasound Med** 1996, 15, 577-584.
151. Shafer et al, **J Microencapsul.** 1994, 11(3), 261-289.

152. Shohet RV, Chen SY and Zhou YT. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. **Circulation** 2000, 101: 2554-2556.
153. Unger EC, McCreery TP and Sweitzer RH. Ultrasound enhances gene expression of liposomal transfection. **Invest Radiol** 1997, 32, 723-727.
154. Unger EC, McCreery TP, Sweitzer RH, Caldwell VE, Wu Y. Acoustically active lipospheres containing paclitaxel: A new therapeutic ultrasound contrast agent. **Invest. Radiol.** 1998, 33, 886-892.
155. Hoff L, Sontum PC, Hoff B. Acoustic properties of shell encapsulated gas-filled ultrasound contrast agent particles. Proceedings of the 1996 IEEE International Ultrasonics Symposium 1996, 21, 287-1292.
156. Hoff L, Sontum P, Hoff B. Acoustic properties of shell encapsulated gas-filled ultrasound contrast agents particles, Proceeding of the 1996 IEEE International Ultrasonic Symposium. 1996, 2, 1441-1444.
157. Kaatz U and Lantscham K. High frequency ultrasound absorption spectroscopy on aqueous suspension of phospholipid bilayer vesicles. **Biophys. Chem.** 1988, 32, 153-160.
158. De Jong N and Hoff L. Ultrasound scattering properties of Albunex microspheres. **Ultrasonic** 1993, 31(3), 175-181.
159. Carstensen EL, Hartman C and Child SZ. Test for kidney hemorrhage following exposure to intense, pulsed ultrasound. **Echocardiography** 1990, 16, 681-685.
160. Porter TR, LeVeen RF and Fox R. Thrombolytic enhancement with perfluorocarbon exposed sonicated dextrose albumin microbubbles. **Am Heart J** 1996, 132, 964-968.

161. Lawrie A, Briskin AF, Francis SE, and Cumberland DC. Microbubble-enhanced ultrasound for vascular gene delivery. **Gene Ther** 2000, 7, 2023–2027.
162. Hynynen K and Giesecke T. Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro. **Ultrasound Med & Biol.** 2003, 29(9), 1359-1365.
163. Holland CK and Apfel RE. Thresholds for transient cavitation produced by pulsed ultrasound in a controlled nuclei environment. **J Acoust Soc Am** 1990, 88, 2059–2069.
164. Miller MW: Gene transfection and drug delivery. **Ultrasound Med Biol** 2000, 26 Suppl 1:S59-S62.
165. Fritz TA, Unger EC, Sutherland G, Sahn D: Phase I clinical trials of MRX-115. A new ultrasound contrast agent. **Invest Radiol** 1997, 32:735-740.
166. The Biomedical Engineering Handbook, Second Edition, ed. J.Bronzino, CRC Handbook, IEEE Press, 2000. pp. 66-17-65-38.
167. Lathia JD, Sherif EI, Dhoot NO and Wheatley MA. Surface modification of polymeric contrast agent for cancer targeting, **Pharmaceutical Engineering.** 2004, 24(1), 1-8.
168. Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S and Miller JG. Contrast echography: current and future applications. **J Am Soc Echocardiogr** 2000, 13, 331 –42.
169. Reilly JP, Tunick PA, Timmermans RJ, Stein B, Rosenzweig BR and Kronzon I. Contrast echocardiography clarifies uninterpretable wall motion in intensive care patients. **J Am Coll Cardiol** 2000, 35, 485 –90.

-
170. Sirlin CB, Lee YZ, Girard MS, Peterson TM, Steinbach GC and Baker KG. Contrast enhanced B-mode US angiography in the assessment of experimental in vivo and in vitro atherosclerotic disease. **Acad Radiol** 2001, 8, 162–72.
171. Hancock J, Dittrich H, Lewitt DE and Monaghan MJ. Evaluation of myocardial, hepatic, and renal perfusion in a variety of clinical conditions using an intravenous ultrasound contrast agent (Optison) and second harmonic imaging. **Heart** 1999, 81, 636–41.
172. Cwajg J, Xie F, O’Leary E, Kricsfeld D, Dittrich H and Porter TR. Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material. **Am Heart J** 2000, 139, 675–83.
173. Swinburn JMA, Lahiri A and Senior R. Intravenous myocardial contrast echocardiography predicts recovery of dysynergic myocardium early after acute myocardial infarction. **J Am Coll Cardiol** 2001, 38, 19–25.
174. Tiemann K, Lohmeier S, Kuntz S, Koster J, Pohl C and Burns P. Real-time contrast echo assessment of myocardial perfusion at low emission power. **Echocardiography** 1999, 16, 799–809.
175. Lafitte S, Higashiyama A, Masugata H, Peters B, Strachan M and Kwan OL. Contrast echocardiography can assess risk area and infarct size during coronary occlusion and reperfusion: experimental validation. **J Am Coll Cardiol** 2002, 39, 1546–54.
176. Galiuto L, May-Newman K, del Balzo U, Flaim SF, Iliceto S and DeMaria AN. Assessment of coronary stenoses of graded severity by myocardial contrast echocardiography. **J Am Soc Echocardiogr** 2002, 1, 197–205.
177. Porter TR, Li S, Jiang L, Grayburn P and Deligonul U. Real time visualization of myocardial perfusion and wall thickening in human beings with intravenous ultrasonographic contrast and accelerated intermittent harmonic imaging. **J Am Soc Echocardiogr** 1999, 12, 266–70.

-
178. Rocchi G, Kasprzak JD, Galema TW, de Jong N and Ten Cate FJ. Usefulness of power Doppler contrast echocardiography to identify reperfusion after acute myocardial infarction. **Am J Cardiol** 2001, 87, 278–82.
179. Fisher NG, Leong-Poi H, Sakuma T, Rim S-J, Bin JP. Detection of coronary stenosis and myocardial viability using a single intravenous bolus injection of BR14. **J Am Coll Cardiol** 2002, 39, 523–9.
180. Masugata H, Peters B, Lafitte S, Strachan GM, Ohmori K and DeMaria AN. Quantitative assessment of myocardial perfusion during graded coronary stenosis by real-time myocardial contrast echo refilling curves. **J Am Coll Cardiol** 2001, 37, 262–9.
181. Porter TR and Xie F. Clinical experience in the detection of coronary artery disease with myocardial contrast echocardiography. **Echocardiography** 2002, 19, 399–407.
182. Main ML, Magalski A, Chee NK, Coen MM, Skolnick DG and Good TH. Full-motion pulse inversion power Doppler contrast echocardiography differentiates stunning from necrosis and predicts recovery of left ventricular function after acute myocardial infarction. **J Am Coll Cardiol** 2001, 38, 1390–4.
183. Goldberg BB, Raichlen JS and Forsberg F, editors. 2nd ed. Ultrasound contrast agents—basic principles and clinical applications. London: Martin Dunitz, 2001.
184. Ronderos RE, Boskis M, Chung N, Corneli DB, Escudero EM and Ha JW. Correlation between myocardial perfusion abnormalities detected with intermittent imaging using intravenous perfluorocarbon microbubbles and radioisotope imaging during high-dose dipyridamole stress echo. **Clin Cardiol** 2002, 25, 103–11.

185. Amyot R, Morales M-A and Rovai D. Contrast echocardiography for myocardial perfusion imaging using intravenous agents: progress and promises. **Eur J Echocardiogr** 2000, 1, 233–43.
186. Hancock J, Dittrich H, Lewitt DE and Monaghan MJ. Evaluation of myocardial, hepatic, and renal perfusion in a variety of clinical conditions using an intravenous ultrasound contrast agent (Optison) and second harmonic imaging. **Heart** 1999, 81, 636–41.
187. Wei K, Le E, Bin JP, Coggins M, Thorpe J and Kaul S. Quantification of renal blood flow. **J Am Soc Cardiol** 2001, 37, 1135–40.
188. Forsberg F, Liu JB, Chiou HJ, Rawool NM, Parker L and Goldberg BB. Comparison of fundamental and wideband harmonic contrast imaging of liver tumors. **Ultrasonics** 2000, 38, 110–3.
189. Foster FS, Burns PN, Simpson DH, Wilson SR, Christopher DA and Goertz DE. Ultrasound for the visualization and quantification of tumor microcirculation. **Cancer Metastasis Rev** 2000, 19, 131–8.
190. Iordanescu I, Becker C, Zetter B, Dunning P and Taylor GA. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US—effect of angiogenesis inhibitors. **Radiology** 2002, 222, 460–7.
191. Seidel G, Meyer K, Metzler V, Toth D, Vida-Langwasser M, Aach T. Human cerebral perfusion analysis with ultrasound contrast agent constant infusion: a pilot study on healthy volunteers. **Ultrasound Med Biol** 2002, 28, 183–9.
192. Seidel G, Claassen L, Meyer K and Vidal-Langwasser M. Evaluation of blood flow in the cerebral microcirculation: analysis of the refill kinetics during ultrasound contrast agent infusion. **Ultrasound Med Biol** 2001, 27, 1059–64.

193. Halpern EJ, Verkh L, Forsberg F, Gomella LG, Mattrey RF and Goldberg BB. Initial experience with contrast-enhanced sonography of the prostate. **Am J Roentgenol** 2000, 174, 1575 – 80.
194. Wilson SR, Burns PN, Muradali D, Wilson JA and Lai X. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. **Radiology** 2000, 215, 153 –61.
195. Maruyama H, Matsutani S, Saisho H, Kamiyama N, Yuki H and Miyata K. Grey-scale contrast enhancement in rabbit liver with DMP115 at different acoustic power levels. **Ultrasound Med Biol** 2000, 26, 1429 –38.
196. Ferrara KW, Merritt CRB, Burns PN, Foster FS, Mattrey RF and Wickline SA. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. **Acad Radiol** 2000, 7, 824 –39.
197. Price RJ, Skyba DM, Kaul S and Skalak TC. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. **Circulation** 1998, 98, 1264 –7.
198. Miller DL and Quddus J. Sonoporation of monolayer cells by diagnostic ultrasound activation of contrast-agent gas bodies. **Ultrasound Med Biol** 2000, 26, 661 –7.
199. Ward M, Wu J and Chiu JF. Experimental study of the effects of Optison concentration on sonoporation in vitro. **Ultrasound Med Biol** 2000, 26, 1169 – 75.
200. Porter TP, Iversen PL, Li S and Xie F. Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon- exposed sonicated dextrose albumin microbubbles. **J Ultrasound Med** 1996, 15, 577 –84.

201. Unger EC, McCreery TP, Sweitzer RH, Caldwell VE and Wu Y. Acoustically active lipospheres containing paclitaxel. A new therapeutic ultrasound contrast agent. **Invest Radiol** 1998, 33, 886–92.
202. Van Liew HD and Burkard ME. High oxygen partial pressure in tissue delivered by stabilized microbubbles. **Adv Exp Med Biol** 1997, 411, 395–401.
203. Lundgren, CEG, Bergoe, GW, Tyssebotn, I. In: Syllabus, 4th International Symposium on Current Issues in Blood Substitute Research, Stockholm, July 2002. p. 40.
204. Unger EC, Hersh E, Vannan M, Matsunaga TO and McCreery T. Local drug and gene delivery through microbubbles. **Prog Cardiovasc Dis** 2001, 44, 45–54.
205. Greenleaf WJ, Bolander ME, Sarkar G, Goldring MB and Greenleaf JF. Artificial cavitation nuclei significantly enhance acoustically induced cell transfection. **Ultrasound Med Biol** 1998, 24, 587–95.
206. Vannan M, McCreery T, Li P, Han Z, Unger E and Kuersten B. Ultrasound-mediated transfections of canine myocardium by intravenous administration of cationic microbubble linked plasmid DNA. **J Am Soc Echocardiogr** 2002, 15, 214-8.
207. Shohet RV, Chen S, Zhou Y-T, Wang Z, Meidell RS and Unger RH. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. **Circulation** 2000, 101, 2554-6.
208. Lawrie A, Briskin AF, Francis SE, Cumberland DC, Crossman DC and Newman CM. Microbubble-enhanced ultrasound for vascular gene delivery. **Gene Therapy** 2000, 7, 2023-7.

-
209. Endoh M, Koibucchi N, Sato M, Morishita R, Kanzaki T and Murata Y. Fetal gene transfer by intrauterine injection with microbubble-enhanced ultrasound. **Mol Therapy** 2002, 5, 501–8.
210. Frenkel PA, Chen S, Thai T, Shohet RV and Grayburn PA. DNA loaded albumin microbubbles enhance ultrasound-mediated transfection in vitro. **Ultrasound Med Biol** 2002, 28, 817–22.
211. Beerli R, Guerrero JL, Supple G, Sullivan S, Levine RA and Hajjar RJ. New efficient catheter-based system for myocardial gene delivery. **Circulation** 2002, 106, 1756–9.
212. Tachibana K, Uchida T, Ogawa K, Yamashita N and Tamura K. Induction of cell-membrane porosity by ultrasound. **Lancet** 1999, 353, 1409.
213. Koch S, Pohl P, Cobet U and Rainov NG. Ultrasound enhancement of liposome-mediated cell transfection caused by cavitation effects. **Ultrasound Med Biol** 2000, 26, 897–903.
214. Martindale - The Extra Pharmacopoeia, 31th edn., J.E.F.Reynolds, ed., The Pharmaceutical Press, London, 1996, p. 575.
215. Physicians' Desk Reference, 53rd ed., Medical Economics Company, Montvale, New Jersey, 1999, p. 2840.
216. Brogden R. and Clissold S. **Drugs**, 1989, 38, 185.
217. Jonler M, Richmann M., and Bruskewitz R. **Drugs**, 1994, 47, 66.
218. Morris J., Hughes L., Glen A. and Taylor P. **J Med. Chem.**, 1991, 34, 447.
219. Cense J., Agafonov V., Ceolin R., Ladure P. and Rodier N. **Struct.Chem.** 1994, 5, 79.

-
220. Ceolin R., Agafonov V., Gonthier-Vassal A., Szwarc H., Cense JM, and Ladure P. **J. Them. Anal.** 1995, 45, 1277.
221. The Merck Index, 12th ed., Merck Co., Inc., Whitehouse Station, New Jersey, 1996, p. 713.
222. Alvarez-Lueje, C. Pena, LJ Nunez-Vergara, and JA Squella. **Electroanalysis**, 1998,10, 1043.
223. Flutamide, United States Pharmacopoeia 23, Fifth Supplement, United States Pharmacopoeial Convention, Inc, Rockville, MD, 1996, p. 3416.
224. Snycerski C. **Pharm. Biomed. Anal.** 1989, 7, 1513.
225. Snycerski JH and. Kalinowski MK. **Pol. J. Chem.** 1992, 66, 49.
226. Zarapkar SS, Damle CD, and Halkar UP. **Indian Drugs**, 1996, 33, 193.
227. Ferenczi-Fodor K. and Vegh Z. **J. Planar Chrom.** 1993, 6, 256.
228. Schering-Plough Research Institute, Unpublished data.
229. Yang Z, Xia Y, Zheng Y. and Xia P. **Yaoxue Xuebao**, 1994, 29, 390.
230. Sane RT, Gangrade MG, Bapat VV, Surve SR, and Chonkar NL. **Indian Drugs**, 1993, 30, 147.
231. D. Farthing, D. Sica, I. Fakhry, D. Walters, E. Cefali. and G. Allan. Gas chromatographic determination of flutamide, nimodipine and ticlopidine HCl from their pharmaceutical preparations. **Biomed. Chrom**, 1994, 8, 251.
232. Xu CJ and Li D. **Zhongguo YaoliXuebao**, 1998, 19, 39.
233. Doser K, Guserle R, Kramer R, Laufer S. and Lichtenberger K. **Arzneim.-Forsch.**, 1997, 47, 213.

-
234. Drummer O, Kotsos A, and McIntyre I. A class independent drug screen in forensic toxicology using a photodiode array detector. **J. Anal. Toxicol.**, 1993, 17, 225.
235. Belanger K., Giasson M., Couture J., Dupont A., Cusan L., and Labrie F.. Plasma levels of hydroxy-flutamide in patients with prostate cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. **Prostate**, 1998, 12, 79.
236. Schulz M., Schmoldt A., Donn F., and Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. **Eur. J. Clin. Pharmacol.** 1988, 34, 633.
237. Radwanski E., Perentesis G., Symchowicz S., and Zampaglione N. Single and Multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. **J. Clin. Pharmacol.** 1989,29, 554.
238. Eulexin Capsule Product Information, copyright 1996, Schering Corporation.
239. USP XIX, 1975 , p.307
240. Lagasca J, Burroughs Wellcome, personal communication
241. P. R. B. Foss, Burroughs Wellcome, unpublished data
242. Crouch R, Burrough Wellcomes, personal communication
243. The Merck Index, 8th Ed. P.658 (1958)
244. Brent D, Burroughs Wellcome, personal communication
245. Fox JJ, Wempen I, Hampton A, **J. Amer. Chem. Soc.**, 1958, 80, 1669.
246. U. S. Patent 2,697,709

-
247. U. S. Patent 2,721,866
248. U. S. Patent 2,724,711
249. U. S. Patent 2,756,828
250. Carthy BJ, Lines CB. Burroughs Wellcome, personal communication.
251. Parrak V, and Tuckermna MM. Oscillopolarography of mercaptopurine and its synthesis intermediates using a commercial oscilloscope and adaptor circuit. **J. Pharm. Sci.**, 1974, 63, 622.
252. Rosenfeld JM, Taguchi VY, Helloccoat BL and Kowai M. Determination of 6-Mercaptopurine in plasma by mass spectrometry. **Anal.Chem.**, 1977,49, 725.
253. Breter HJ et al. The quantitative determination of metabolites of 6-Mercaptopurine in biological materials. **Anal. Biochem.**, 1977, 80, 9.
254. Chalmers AH et al. **Biochem. Med.**, 1975, 12, 234.
255. Bailey DG, Wilson TW and Johnson GE. A gas chromatographic method for measuring 6-mercaptopurine in serum. **J. Chrom.**, 1975, 111, 305.
256. Harber MJ, Maddocks JL. Separation of plasma analogues from nucleic acid derivatives on a thin layer of ecteola cellulose. **J. Chrom.**, 1974, 101, 231.
257. Maddocks JL, Davison GS. Separation and detection of picomole quantities of azathioprine derivatives. **Brit. J. Clin. Pharm.**, 1979, 2, 359.
258. Elion GB, Beber S, Hitchings GH. **Ann. N. Y. Acad. Sci.**, 1954, 60, 297.
259. Donelli MG, Columbo T, Forgione A, Garattini S, **Pharmacol.**, 1972, 8, 311.

-
260. Adamson RH. *Ann. N. Y. Acad. Sci.*, 1971, 179, 432.
261. Sarcione EJ and Stulzman L, *Can. Res.*, 1960, 20, 387.
262. Stewart JCM. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. *Anal. Biochem.* 1980, 104: 10-14.
263. New RRC. Miscellaneous methods in Liposomes: A Practical Approach. New RRC (ed.), Oxford University Press, Oxford, 1990, 252-266.
264. Zlatkis A, Zak B and Boyle AJ. A new method for the direct determination of serum cholesterol. *J. Lab. Clin Med.* 1953, 41: 486-492.
265. Squella JA, Pena C and Alvarez-Lueje A. *Electroanalysis* 1998, 10(15), 1043-51.
266. Miranda A., Caraballo I. And Millan M., *Drug Dev. Ind. Pharm.* 2002, 28(4), 413 – 422.
267. Camarero MA, Sacaba B and Garcia-Quelglas E. *J.Chromatogr.B.* 1998, 706 311-317.
268. Zhong Z, Yum KT, Diakur J. *J. Pharm. Pharm.Sci.* 2002, 5(3) 292-298.
269. M. Merodia, T. Mirshahi, M. Mirshahi, *J.Chromatogr.* 2000, 870 159-167.
270. Erb N, Haverland, U, Harms DO, Escherich G and Janka-Schaub G. High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2003, 796(1), 87-94.
271. Oliveira BM, Romanha AJ, Alves TM, Viana MB and Zani CL. An improved HPLC method for the quantitation of 6-mercaptopurine and its metabolites in red blood cells. *Braz. J. Med. Biol Res.* 2004, 37(5), 649-58.

-
272. Su Y, Hon YY, Chu Y, Van de Poll ME and Relling MV. Assay of 6-MP and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection. **Chromatogr B Biomed. Sci. Appl.** 1999, 732(2), 459-68.
273. Welch J, Lennard L, Morton GC and Lilleyman JS. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose. **Ther. Drug Monit.** 1997, 19(4), 382-5.
274. Tang, J, Zhou S, Huang L, Huang Y and Zhang H. Determination of azathiopurine and 6-mercaptopurine in serum by reversed-phase high performance liquid chromatography. **Se Pu.** 1998, 16(6), 513-5.
275. Camarero MA, Sacaba B and Garcia-Quelglas E **J.Chromatogr.B** 1998, 706, 311-317.
276. Innocenti F, Danesi R, Bocci G, Fogli S, Di Paolo A and Del-Tacca M. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens. **Cancer Chemother. Pharmacol.** 1999, 43(2), 133-40.
277. Baker JW, Bachman GL, Schumacher I, Raman DP and Thorp A. Synthesis and bacteriostatic activity of nirtrofluoromethylenilides. **J. Med. Chem.** 1967, 10, 93-95.
278. Asade RH, Prizont L, Muino JP and Tessler J. Steady state hydroxyflutamide plasma levels after the administration of two dosage forms of flutamide. **Cancer Chemother. Pharmacol.** 1991, 27, 401-405.
279. Gomez JZ, Dupont A, Cusan L, Tremblay M, Suburo R, Lemay M and Labrie F. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. **Am. J. Med.** 1992, 92, 465-470.

-
280. Betagiri GV, Jenkins SA and Parsons DL. Preparation of liposomes. liposomal drug delivery systems, 10th Ed; Technomic Publications: Lancaster, 1993; 1-26
281. Knight CG. From physical structure to therapeutic application. liposomes, Elsevier/North-Holand Biomedical Press: New York, 1981.
282. Bangham AD, Standish MM and Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. **J. Mol. Biol.** 1965, 13, 238-252.
283. Armstrong NA and James KC. Understanding experimental designs and interpretation in pharmaceutics, Ellis Horwood Publications: London, UK, 1990; 27-54.
284. Paterakis PG, Korakianiti ES, Dallas PP and Rekas DM. evaluation and simultaneous optimization of some pellets characteristics using 3³ factorial design and the desirability function. **Int. J. Pharm.** 2002, 248(1), 51-60.
285. Juslin L, Antikainen O, Mercku P and Yliruusi J. droplet size measurement: I. effect of three independent variables on droplet size distribution and spray angle from a pneumatic nozzle. **Int. J. Pharm.** 1995, 123, 247-256.
286. Betagiri GV, Jenkins SA and Parsons DL. Stability of liposomes. Liposomal drug delivery systems, 10th Ed; Technomic Publications: Lancaster, 1993; 27-56.
287. Schulz M, Schmoldt A, Donn F and Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. **Eur. J. Clinical. Pharmacol.** 1988, 34, 633-636.
288. Bhalerao SS and Harshal AR. preparation, optimization, characterization and stability studies of salicylic acid liposomes. **Drug Dev. Ind. Pharm.** 2003, 29(4), 451-467.

-
289. Abuchowski A, Es TV, Palczuk NC and Davis FF. alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. **J.Biol Chem.** 1977, 252, 3578-3581.
290. Blume G and Cevc G. Liposomes for the sustained drug release in vivo. **Biochem. Biophys. Acta.** 1990, 1029, 91-97.
291. Namba Y and Oku N. Liposomal applications to cancer therapy, **J. Bioact. Compat. Polym.** 1993, 8, 158-177.
292. Zimm S, Collins JM, Riccardi R., O'Neill D, Narang PK and Chabner B. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? **N. Engl. J. Med.** 1983, 308, 1005.
293. Lockhart S, Plunkett W, Jeha S, Ramirez I, Zipf T, Cork A and Pinkel D. High-dose mercaptopurine followed by intermediate- dose cytarabine in relapsed acute leukemia. **J Clin Oncol** 1994, 12, 587
294. A Sharma and U S Sharma. Liposomes in drug delivery: progress and limitations. **Int J Pharm.** 1997, 154, 123-140.
295. Lasic DD and Papahadjopoulos D. Liposomes revisited. **Science** 1995, 267, 1275-1276.
296. Umrethia ML and Murthy RSR. Optimization of formulation parameters of flutamide liposomes by 3^3 factorial 26-term logit model. **Pharm. Dev Tech.** 2004, 9(4), 369-378.
297. Betagiri GV, Jenkins SA and Parsons DL. Stability of Liposomes. **Liposomal Drug Delivery Systems**, 10th Ed; Technomic Publications: Lancaster, 1993 27-56.

-
298. Lachman L, Lieberman HA and Kanig JL. Statistical Applications in the pharmaceutical sciences. The Theory and Practice of Industrial Pharmacy, 3rd Ed; Vaghesse Publications: Bombay, 1987; 243-292.
299. D' Arrigo, J.S. 1987. U.S.Patent No. 4, 684, 479.
300. D' Arrigo, JS. 1986. Stable gas in liquid emulsions: Production in natural waters and artificial media, 220 pp.l Elsevier Science Publishers, Amsterdam.
301. D' Arrigo JS. 1993. U.S.Patent No. 5, 215, 680.
302. D' Arrigo JS and Imae T. Physical characteristics of ultrastable lipid-coated microbubbles. **J. Colloid and Interface Sci.** 1992, 149, 592-595.
303. Maddox J, Schmidt T and Ostafin A. Synthesis control and analysis of aqueous cored calcium phosphate nanoparticles. Summer Research Paper, May 18 - August 6, 2004.
304. Sagristá L. Mora M. and DeMadariaga A. Surface modified liposomes by coating with charged hydrophilic molecules. **Cellular & Molecular Biology Letters**, 2000, 5, 19-33.
305. Garbuzenko O, Zalipsky S, Qazen M and Barenholz Y. Electrostatics of pegylated micelles and liposomes containing charged and neutral lipopolymers. **Langmuir** 2005, 21, 2560-2568.
306. Schwartz MA, and McConnell HM. Surface areas of lipid membranes. **Biochemistry.** 1978, 17, 837-840.
307. Fresta M, Chillemi R, Spampinato S, Sciuto S, and Puglisi G. Liposomal delivery of a 30-Mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. **J. Pharm. Sci.** 1999, 87, 616-625.

-
308. New RC. Preparation of liposomes. *Liposomes: A practical approach*, New RC (ed.) Oxford University Press, Oxford, 1990, 33-140.
309. Burner H, Winterhalter M and Benz R. Interaction of poly (ethylene glycol) with air-water interfaces and lipid monolayers: investigations on surface pressure and surface potential. *J. Colloid Interface Sci.* 1994, 168, 183-189.
310. Lohner K, Staudegger E, Prenner JE, Lewis H, Kriechbaum M, Degovics G and McElhaney NR, *Biochemistry*, 1999, 38, 16514-16528.
311. Haranczyk H, Strzaka K, Dietrich W and Blicharski JS. *J. Biol. Phys.* 1995, 21, 125-139.
312. Rajan S, Kang SY, Gutowsky HS and Oldfield E. Phosphorous nuclear magnetic resonance study of membrane structure. Interactions of lipid with protein, polypeptides and cholesterol. *J. Biol. Chem.* 1981, 256, 1160-1166.
313. Shulkin PM, Selter SE, Davis MA and Adams DF. Lyophilized liposomes: a new method for long-term vesicular storage. *J. Microencap.* 1984, 1, 73-80.
314. Crowe JH, Crowe LM and Carpenter JF. Interaction of sugars with membranes. *Biochim. Biophys. Acta*, 1988, 947, 367-384.
315. Tanaka K, Takeda T, Fuji K and Miyajima K. Cryoprotective mechanism of saccharides on freeze-drying of liposomes. *Chem.Pharm.Bull.* 1992, 40, 1-5.
316. Koster KL, Webb MS, Bryant G and Lynch DV. Interactions between soluble sugars and POPC during dehydration: vitrification of sugars alters the phase behavior of the phospholipid. *Biochim. Biophys. Acta.* 1994, 1193, 143-150.
317. Mobley WC and Schreier H. Phase transition temperature and glass formation in dehydro protectant lyophilized liposomes. *J. Control Rel.* 1994 31 73-87.

-
318. Dean JA (ed.). Lange's Handbook of Chemistry. 15th edn., McGraw Hill Inc., New York, 1996: 116.
319. Pomerat CM and Leake CD. Short term cultures for drug assays: general considerations. *Ann. New York Acad. Sci* 1954, 58, 110-1128.
320. Eagle H and Foley GE. The cytotoxic action of carcinolytic agents ill tissue culture. *Am. J. Med.* 1956, 21, 739- 745.
321. Smith CG, Grady JE and Northam JI. Relationship between cytotoxicity in vitro and whole animal toxicity. *Cancer Chemoth. Rep* 1963, 30, 9-12.
322. Phillips JC, Gibson WB, Yam J, Alden CL and Hard GC. Survey of the QSAR and *in vitro* approaches for developing non-animal methods to supersede the *in vivo* LD₅₀ test. *Food Chem. Toxicol.* 1990, 28, 375-394.
323. Garle M, Fentem JH and Fry JR. *In vitro* cytotoxicity tests for the prediction of acute toxicity *in viv*). *Toxicol. In Vitro.* 1994, 8, 1303-1312.
324. Curren R, Bruner L, Goldberg A and Walum E. 13th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC): Validation and acute toxicity testing. *Environ. Health Persp.* 1998, 106 (Suppl. 2), 419-425.
325. Ekwall B, Ekwall B and Sjostrom M. MEIC evaluation of acute systemic toxicity: Part VIII. Multivariate partial least squares evaluation, including the selection of a battery cell line tests with a good prediction of human acute lethal peak blood concentrations for 50 chemicals. *ATLA* 2000, 28 (Suppl. 1), 201-234.
326. Ohno T, Futamura Y and Harihara P. Validation study on five cytotoxicity assays by JSAAE. VI. Details of the LDH release assay. *AATEX.* 1998, 5, 99-114.

327. Ohno T, Asakura M and Awogi T. Validation study on five cytotoxicity assays by JSAAE. I. Overview of true study and analyses of variations of ED50 values. *AATEX*. 1998, 5, 1-38.
328. Ohno T, Futamura Y and Harihara A. Validation study on five cytotoxicity assays by JSAAE. VIII. Details of the neutral red uptake assay. *AATEX* 1998, 5, 131-145.
329. Seibert H, Balls M and Fentem JH. Acute toxicity testing in vitro and the classification and labeling of chemicals. **The report and recommendations of ECVAM Workshop 16**. ATLA; 1996, 24, 499-510
330. Spielmann H. Balls M, Dupuis J, Paper WJW and Pechovitch G. EU/COLIPA "In vitro phototoxicity" validation study results of phase II (blind trial), Part 1: the 3T3 NRU phototoxicity test, *Toxicol In Vitro* 1998a, 12, 305-327.
331. Mosmann T. Rapid Colorimetric assay for cellular growth and survival: **Application to proliferation Methods**. 1983, 6555-63.
332. Dosio F, Brusa P, Crosasso P and Arpicco S. Preparation, Characterization properties, in vitro and in vivo of paclitaxel albumin conjugate. *J. Control. Rel.* 1997, 47, 293-304.
333. Zhong Z and Diakur J. Hydroxypropyl-B-cyclodextrin-flutamide inclusion complex II. Oral and intravenous pharmacokinetics of flutamide in the rat. *J Pharm and Pharm Sci.* 2002, 5(3), 292-298.
334. Gibaldi, M and Perrier, D. *Pharmacokinetics*, Marcel Dekker, Inc.: New York, 1982. p. 409-416.
335. Allen TM. Liposomal drug formulations- rationale for development and what we can expect from the future? *Drugs* 1998, 56(5), 747-756.

-
336. Gabizon A and Catane R. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes **Cancer Research** 1994, 54 (4), 987-992.
337. Gabizon G and Papahadjopoulos D. Liposomes formulation with prolonged circulation time in blood and enhance uptake by tumors. **Proceedings of the National Academy of Sciences USA**. 1988, 856949-6953.
338. Woodle MC. Surface-modified liposome-assessment and characterization for increased stability and prolong blood circulation. **Chemistry and Physics of Lipids** 1993, 64(1-3), 249-262.
339. Lee JCM and Bermudez H. Preparation, stability and in-vivo performance of vesicles made with diblock copolymers. **Biotechnology and Bioenergetics** 2001, 73 (2), 135-145.
340. Liu DX and Liu F. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonins. **Biochim et Biophys Acta-Biomem** 1995, 1235, 140-146.
341. Efremova NK and Bondurant B. Measurements of interbilayer forces and protein adsorption on uncharged lipid bilayers displaying poly (ethylene glycol) chains. **Biochemistry**. 2000, 39,3441-3451.
342. Federico I, Antonello DP and Barbara L. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. **Cancer Chemother. Pharmacol**. 1996, 37, 409-414.
343. Zimm S, Collins JM, O'Neill D, Chabner BA and Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. **Clin. Pharmacol. Ther.** 1983, 34, 810.

344. Lennard L, Keen D and Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. **Clin. Pharmacol. Ther.** 1986, 40, 287.
345. Lennard L, Lilleyman JS, Van Loon J and Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. **Lancet.** 1990, 336, 225.
346. Lennard L and Lilleyman, JS. Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. **J Clin Oncol**, 1989, 7, 1816.
347. Ozonol S and Kawakami T. Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. **Prostate Cancer and Prostatic Diseases** 2002, 5:128–131.
348. Huang L. Covalently attached polymers and glycans to alter the biodistribution of liposomes. **J Lip Res.** 1992, 2:289-291.
349. Kim CK and Han JH. Pharmacokinetics and tissue distribution of methotrexate after intravenous injection of differently charged liposome-entrapped methotrexate to rats. **Int J Pharm** 1994, 108:21-29.
350. Oku N. Anti-cancer therapy using glucuronate modified long-circulating liposomes. **Advanced Drug Delivery Review**, 1999, 40:63-73.
351. Gabizon G and Papahadjopoulos D. Liposomes formulation with prolonged circulation time in blood and enhance uptake by tumors. **Pro. Nat. Acad. Sci. USA.**, 1988, 85, 6949-6953.
352. Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, eds. Diseases of the liver. Philadelphia: J.B. Lippincott, 1993.
353. Kaplowitz N. Drug metabolism and hepatotoxicity. In: Kaplowitz N, ed. Liver and biliary diseases. Baltimore: Williams and Wilkins, 1991.

-
354. Farrell GC. Drug-induced liver disease. Edinburgh, Scotland: Churchill Livingstone, 1994.
355. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. **J Pharmacol Exp Ther** 1973; 187:211-7.
356. Baerg RD and Kimberg DV. Centrilobular hepatic necrosis and acute renal failure in "solvent sniffers". **Ann Intern Med** 1970, 73, 713-20.
357. Klein AS, Hart J, Brems JJ, Goldstein L, Lewin K and Busuttil RW. Amanita poisoning: treatment and the role of liver transplantation. **Am J Med** 1989, 86,187-93.
358. Gittes RF. Carcinoma of the prostate. **N Engl J Med**. 1991,324, 236-45.
359. Hart W and Stricker BH Ch. Flutamide and hepatitis (Letter). **Ann Intern Med**. 1989,110, 943-4.
360. Moller S, Iversen P and Franzmann MB. Flutamide-induced liver failure. **J Hepatol**. 1990,10,346-9.
361. Coppere H, Perraud Y, Gerard F, Jouffre C, David A, Barthelemy C, et al. Un cas d'hepatite aigue au flutamide. (A case of acute hepatitis caused by flutamide (letter)). **Gastroenterol Clin Biol**. 1990, 14,105-6.
362. Alperine M, Cohen L, Cocheton JJ, Lecomte I and Meyniel D. Hepatite aigue due au flutamide. (Acute hepatitis caused by flutamide (Letter)). **Presse Med**. 1991, 20, 1459-60.
363. Corkery JC, Bihrlle W 3d, McCaffrey JA, Whitcomb FF, Levy C and Ellis R. Flutamide-related fulminant hepatic failure (Letter). **J Clin Gastroenterol**. 1991,13, 364-5.

-
364. Van Scoik KG, Johnson CA and Porter WR. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. **Drug Metab Rev** 1985, 16:157–174.
365. McLeod HL, Krynetski EY, Relling MV and Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. **Leukemia** 2000, 14: 567–572.
366. Beaune PH and Bourdi M. Autoantibodies against cytochromes P-450 in drug induced autoimmune hepatitis. **Ann N Y Acad Sci** 1993, 685,641-5.
367. Lee WM. Drug-induced hepatotoxicity. **The New England Journal of Medicine**, 1995, 333(17), 1118-1127.
368. Arridge SR and Hebden JC. Optical imaging in medicine. Modelling and Reconstruction. **Phys. Med. Biol.** 1997, 42, 841-43.
369. Kinsler Le, Frey AR, Copper AB and Sanders JV. Fundamental of acoustics. 3rd Edition, 1982, John-Wiley and Sons, New York.